PMID- 27439539
OWN - NLM
STAT- MEDLINE
DCOM- 20170609
LR  - 20181113
IS  - 1535-3699 (Electronic)
IS  - 1535-3702 (Print)
IS  - 1535-3699 (Linking)
VI  - 241
IP  - 18
DP  - 2016 Dec
TI  - Effects of iron supplementation in mice with hypoferremia induced by obesity.
PG  - 2049-2055
LID - 10.1177/1535370216660398 [doi]
AB  - Iron is an important micronutrient, but it can also act as a dangerous element by 
      interfering with glucose homeostasis and inflammation, two features that are 
      already disturbed in obese subjects. In this work, we study the effects of 
      systemic iron supplementation on metabolic and inflammatory responses in mice 
      with hypoferremia induced by obesity to better characterize whether iron worsens 
      the parameters that are already altered after 24 weeks of a high-fat diet (HFD). 
      Mice were maintained on a control diet or a HFD for 24 weeks and received 
      iron-III polymaltose (50 mg/kg/every 2 days) during the last two weeks. Glucose 
      homeostasis (basal glucose and insulin test tolerance) and systemic and visceral 
      adipose tissue (VAT) inflammation were assessed. Iron levels were measured in 
      serum. The Prussian blue reaction was used in isolated macrophages to detect iron 
      deposition. Iron supplementation resulted in an increased number of VAT 
      macrophages that were positive for Prussian blue staining as well as increased 
      serum iron levels. Systemic hepcidin, leptin, resistin, and monocyte 
      chemoattractant protein-1 (MCP-1) levels were not altered by iron 
      supplementation. Local adipose tissue inflammation was also not made worse by 
      iron supplementation because the levels of hepcidin, MCP-1, leptin, and 
      interleukin (IL)-6 were not altered. In contrast, iron supplementation resulted 
      in an increased production of IL-10 by adipose tissue and VAT macrophages. 
      Leukocytosis and VAT plasminogen activator inhibitor-1 (PAI-1) level were 
      reduced, but insulin resistance was not altered after iron supplementation. In 
      conclusion, systemic iron supplementation in mice with hypoferremia induced by 
      obesity did not worsen inflammatory marker or adipose tissue inflammation or the 
      metabolic status established by obesity. Iron deposition was observed in adipose 
      tissue, mainly in macrophages, suggesting that these cells have mechanisms that 
      promote iron incorporation without increasing the production of inflammatory 
      mediators.
FAU - Gotardo, Erica Martins Ferreira
AU  - Gotardo EM
AD  - Clinical Pharmacology and Gastroenterology Unit, Sao Francisco University Medical 
      School, Braganca Paulista 12916-900, SP, Brazil.
FAU - Caria, Cintia Rabelo E Paiva
AU  - Caria CR
AD  - Clinical Pharmacology and Gastroenterology Unit, Sao Francisco University Medical 
      School, Braganca Paulista 12916-900, SP, Brazil.
FAU - de Oliveira, Caroline Candida
AU  - de Oliveira CC
AD  - Clinical Pharmacology and Gastroenterology Unit, Sao Francisco University Medical 
      School, Braganca Paulista 12916-900, SP, Brazil.
FAU - Rocha, Thalita
AU  - Rocha T
AD  - Clinical Pharmacology and Gastroenterology Unit, Sao Francisco University Medical 
      School, Braganca Paulista 12916-900, SP, Brazil.
FAU - Ribeiro, Marcelo Lima
AU  - Ribeiro ML
AD  - Clinical Pharmacology and Gastroenterology Unit, Sao Francisco University Medical 
      School, Braganca Paulista 12916-900, SP, Brazil.
FAU - Gambero, Alessandra
AU  - Gambero A
AD  - Clinical Pharmacology and Gastroenterology Unit, Sao Francisco University Medical 
      School, Braganca Paulista 12916-900, SP, Brazil.
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20160724
PL  - Switzerland
TA  - Exp Biol Med (Maywood)
JT  - Experimental biology and medicine (Maywood, N.J.)
JID - 100973463
RN  - 0 (Blood Glucose)
RN  - 0 (Cytokines)
RN  - 0 (Ferric Compounds)
RN  - 0 (Hepcidins)
RN  - E1UOL152H7 (Iron)
RN  - UM5219H89V (teferrol)
SB  - IM
MH  - Anemia, Iron-Deficiency/drug therapy/*etiology
MH  - Animals
MH  - Blood Glucose/analysis
MH  - Cytokines/blood
MH  - Dietary Supplements
MH  - Ferric Compounds/*therapeutic use
MH  - Hepcidins/blood
MH  - Inflammation/drug therapy/etiology
MH  - Intra-Abdominal Fat/drug effects/metabolism
MH  - Iron/blood
MH  - Male
MH  - Mice
MH  - Obesity/*complications
PMC - PMC5102132
OTO - NOTNLM
OT  - Hepcidin
OT  - adipokine
OT  - adipose tissue
OT  - adipose tissue macrophage
EDAT- 2016/07/22 06:00
MHDA- 2017/06/10 06:00
PMCR- 2017/06/01
CRDT- 2016/07/22 06:00
PHST- 2016/07/22 06:00 [pubmed]
PHST- 2017/06/10 06:00 [medline]
PHST- 2016/07/22 06:00 [entrez]
PHST- 2017/06/01 00:00 [pmc-release]
AID - 1535370216660398 [pii]
AID - 10.1177_1535370216660398 [pii]
AID - 10.1177/1535370216660398 [doi]
PST - ppublish
SO  - Exp Biol Med (Maywood). 2016 Dec;241(18):2049-2055. doi: 
      10.1177/1535370216660398. Epub 2016 Jul 24.